12:00 AM
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tasigna nilotinib: Phase III data

Novartis disclosed in its 3Q09 earnings that Tasigna missed the primary endpoint of significantly improved PFS in a Phase III trial for third-line treatment of GIST. The company also said Tasigna did...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >